The analysis of patient records found no elevated risk of retinopathy among those using glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes.
Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with increased risk of incident diabetic retinopathy, according to a study published in Diabetes Care.
GLP-1 receptor agonists (RAs) lower blood sugar levels by promoting insulin secretion. Patients who use these drugs to treat type 2 diabetes not only see improved glycemic control but may also lose weight. In fact, one GLP-1 therapy, liraglutide, is approved in a formulation to treat obesity. Studies have also been published showing cardiovascular benefits for liraglutide and semaglutide, and FDA granted a cardiovascular indication for liraglutide last year.
Read About Once-Weekly Semaglutide
The SUSTAIN-6 study had pointed to a possible worsening of retinopathy with semaglutide, although this was not borne out in the SUSTAIN-7 trial prior to approval. The claims study published this week evaluated data from 77,115 patients in the United Kingdom who had type 2 diabetes (T2D) and began taking therapies between January 2007 and September 2015. Researchers compared those taking GLP-1 RAs with those taking 2 or more oral antidiabetic drugs and, in a separate analysis, compared those taking GLP-1 RAs with those taking insulin.
During 245,825 person-years of follow-up, 10,763 patients were newly diagnosed with diabetic retinopathy. Compared with those taking 2 or more oral drugs, the risk of retinopathy among those taking the GLP-1 class was the same (hazard ratio [HR], 1.00; 95% CI, 0.85-1.17). Those taking the GLP-1 class had a 33% reduced risk of retinopathy compared with those taking insulin (HR, 0.67; 95% CI, 0.51-0.90). The authors wrote that the apparent lower risk of diabetic retinopathy may be due to residual confounding.
Reference
Douros A, Filion KB, Yin H, et al. Glucagon-like peptide-1 receptor agonists and the risk of incident diabetic retinopathy [published online August 27, 2018]. Diabetes Care. 2018. doi: 10.2337/dc17-2280.
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Interactive mHealth App Helped Improve Patients’ Lifestyle Habits After Undergoing PCI
April 29th 2024These lifestyle improvements included adherence to the Mediterranean diet, improved frequency of healthy food consumption, increased physical activity, and quitting smoking, among other factors.
Read More